Refusal to market new drugs

New drugs that can counteract tuberculosis are ready for testing, but the American pharmaceutical industry refuses to pay to test and market them due to the costs involved, which it claims are $200 million US. It says that the US market for the drug is too small to recover its costs, entirely ignoring about 1.75 billion tubercular people outside its borders who need the drugs. There is no American or global agency that can legally force the pharmaceutical companies to sell their products.

1. Critics state that $200 million US is too high an estimate of testing and marketing costs.

1. Restrictive practices in trade in pharmaceutical products
2. Refusal to sell
3. Refusal to provide medical treatment
4. Ineffective self-regulation in the pharmaceutical and medical devices industries
5. Commercial exploitation of health
6. Blocked global marketing
7. Applied double standards

1. Weakness in trade among developing countries
2. Tuberculosis
3. Malaria
4. Inadequate primary health care

1. Unacknowledged global interdependence
2. Parochial leadership posture
3. Non-accountability of transnational enterprises
4. Minimal export promotion by transnational corporations
5. Lack of social accounting in the business community
6. Insensitivity to the plight of disadvantaged people
7. Inadequate global policy-making
8. Global parochialism
9. Commercial disregard of social responsibility

1. Suppression of scientific information

1. Undeveloped
2. Underdevelopment
3. Self-denial
4. Refusal
5. Overdevelopment
6. Health
7. Development
8. Denial